{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:16:20Z","timestamp":1789877780868,"version":"4.0.1"},"reference-count":38,"publisher":"Impact Journals, LLC","issue":"39","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,5,22]]},"DOI":"10.18632\/oncotarget.25424","type":"journal-article","created":{"date-parts":[[2018,5,19]],"date-time":"2018-05-19T06:35:34Z","timestamp":1526711734000},"page":"25617-25629","source":"Crossref","is-referenced-by-count":12,"title":["Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma"],"prefix":"10.18632","volume":"9","author":[{"given":"Anne","family":"Aarnink","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Center Georges Francois Leclerc, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin","family":"Richard","sequence":"additional","affiliation":[{"name":"Platform of Transfer in Oncology, Besan\u00e7on University Hospital, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Truntzer","sequence":"additional","affiliation":[{"name":"Platform of Transfer in Oncology, Besan\u00e7on University Hospital, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Vincent","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Center Georges Francois Leclerc, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Bengrine","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Center Georges Francois Leclerc, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lique","family":"Vienot","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Besan\u00e7on University Hospital, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Borg","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Besan\u00e7on University Hospital, Besan\u00e7on, France"},{"name":"University of Bourgogne-Franche-Comt\u00e9, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Ghiringhelli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Center Georges Francois Leclerc, Dijon, France"},{"name":"Platform of Transfer in Oncology, Besan\u00e7on University Hospital, Besan\u00e7on, France"},{"name":"INSERM, Unit 1231, Besan\u00e7on, France"},{"name":"University of Bourgogne-Franche-Comt\u00e9, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,5,22]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/annonc\/mdt010","article-title":"European cancer mortality predictions for the year 2013","volume":"24","author":"Negri","year":"2013","journal-title":"Ann Oncol"},{"key":"2","volume-title":"Cancer Facts & Figures 2012","author":"Society AC","year":"2012"},{"key":"3","volume-title":"Cancer Facts & Figures 2013","author":"Society AC","year":"2013"},{"key":"4","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3748\/wjg.v17.i7.867","article-title":"Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010","volume":"17","author":"Molinari","year":"2011","journal-title":"World J Gastroenterol"},{"key":"5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/SLA.0b013e3180691579","article-title":"National failure to operate on early stage pancreatic cancer","volume":"246","author":"Talamonti","year":"2007","journal-title":"Ann Surg"},{"key":"6","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/s0140-6736(10)62307-0","article-title":"Pancreatic cancer","volume":"378","author":"Goggins","year":"2011","journal-title":"Lancet"},{"key":"7","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Stephens","year":"1997","journal-title":"J Clin Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Khemissa-Akouz","year":"2011","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Dowden","year":"2013","journal-title":"N Engl J Med"},{"key":"10","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ejso.2007.09.007","article-title":"Effect of preoperative chemotherapy on liver resection for colorectal liver metastases","volume":"34","author":"Mirza","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/SLA.0b013e31815774de","article-title":"Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy","volume":"247","author":"Jaeck","year":"2008","journal-title":"Ann Surg"},{"key":"12","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1200\/jco.2005.05.3074","article-title":"Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases","volume":"24","author":"Capussotti","year":"2006","journal-title":"J Clin Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.immuni.2013.10.010","article-title":"The spleen in local and systemic regulation of immunity","volume":"39","author":"Pittet","year":"2013","journal-title":"Immunity"},{"key":"14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Dodd","year":"2009","journal-title":"Eur J Cancer"},{"key":"15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s003300050145","article-title":"Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus","volume":"7","author":"Gourtsoyiannis","year":"1997","journal-title":"Eur Radiol"},{"key":"16","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1093\/bioinformatics\/btp088","article-title":"Boosting for high-dimensional time-to-event data with competing risks","volume":"25","author":"Beyersmann","year":"2009","journal-title":"Bioinformatics"},{"key":"17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.21873\/invivo.11122","article-title":"Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine","volume":"31","author":"Hebbar","year":"2017","journal-title":"In Vivo"},{"key":"18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2017.05.005","article-title":"Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies","volume":"58","author":"Yang","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41598-017-00859-5","article-title":"Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma","volume":"7","author":"Dai","year":"2017","journal-title":"Sci Rep"},{"key":"20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.pan.2013.09.005","article-title":"Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients?","volume":"13","author":"Melichar","year":"2013","journal-title":"Pancreatology"},{"key":"21","doi-asserted-by":"publisher","first-page":"6956","DOI":"10.1158\/1078-0432.ccr-04-0224","article-title":"The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma","volume":"10","author":"Mackey","year":"2004","journal-title":"Clin Cancer Res"},{"key":"22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/his.12577","article-title":"Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies","volume":"66","author":"Demetter","year":"2015","journal-title":"Histopathology"},{"key":"23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2217\/bmm.13.48","article-title":"Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?","volume":"7","author":"Dumontet","year":"2013","journal-title":"Biomark Med"},{"key":"24","doi-asserted-by":"publisher","first-page":"djt347","DOI":"10.1093\/jnci\/djt347","article-title":"Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial","volume":"106","author":"McDonald","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.gastro.2008.09.067","article-title":"Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer","volume":"136","author":"Mackey","year":"2009","journal-title":"Gastroenterology"},{"key":"26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/hepr.12107","article-title":"Evaluation and management of hepatic injury induced by oxaliplatin-based chemotherapy in patients with hepatic resection for colorectal liver metastasis","volume":"44","author":"Utsunomiya","year":"2014","journal-title":"Hepatol Res"},{"key":"27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/SLA.0b013e3181c79403","article-title":"Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome","volume":"251","author":"Scatton","year":"2010","journal-title":"Ann Surg"},{"key":"28","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/cncr.23099","article-title":"Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases","volume":"110","author":"Vauthey","year":"2007","journal-title":"Cancer"},{"key":"29","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1200\/jco.2009.27.5701","article-title":"Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury","volume":"28","author":"Kopetz","year":"2010","journal-title":"J Clin Oncol"},{"key":"30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.cir-16-0297","article-title":"Myeloid-Derived Suppressor Cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment","volume":"37","author":"Gabrilovich","year":"2016","journal-title":"Trends Immunol"},{"key":"32","doi-asserted-by":"publisher","first-page":"24380","DOI":"10.18632\/oncotarget.15456","article-title":"Neutrophil count is associated with myeloid derived suppressor cell level and presents prognostic value of for hepatocellular carcinoma patients","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"key":"33","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00262-017-1977-z","article-title":"Myeloid cells in circulation and tumor microenvironment of breast cancer patients","volume":"66","author":"Elkord","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/exd.12336","article-title":"Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients","volume":"23","author":"Tuettenberg","year":"2014","journal-title":"Exp Dermatol"},{"key":"35","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1111\/j.1582-4934.2009.00685.x","article-title":"Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells","volume":"13","author":"Abrams","year":"2009","journal-title":"J Cell Mol Med"},{"key":"36","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/hepr.12167","article-title":"Increased circulating Lin(-\/low) CD33(+) HLA-DR(-) myeloid-derived suppressor cells in hepatocellular carcinoma patients","volume":"44","author":"Zheng","year":"2014","journal-title":"Hepatol Res"},{"key":"37","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1158\/0008-5472.CAN-15-3164","article-title":"Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen","volume":"76","author":"Delmas","year":"2016","journal-title":"Cancer Res"},{"key":"38","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/m14-0698","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T18:19:58Z","timestamp":1589048398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,22]]},"references-count":38,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2018,5,22]]}},"alternative-id":["25424","29876012"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.25424","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,22]]}}}